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TO THE EDITOR—We read with interest the
article by Wójtowicz et al [1], and would
like to comment on it and to share ﬁnd-
ings from our complementary study. We
have recently established genetic varia-
tion in the long pentraxin 3 (PTX3) as a
major determinant of susceptibility to in-
vasive aspergillosis (IA) after hematopoi-
etic stem cell transplant [2]. Wójtowicz
et al are the ﬁrst to uncover similar ﬁnd-
ings in solid organ transplant (SOT)
recipients, highlighting a potential appli-
cability of these markers in predicting in-
fection across patients with intrinsically
different predisposing conditions.
We commend Wójtowicz et al on their
robust study design and analysis. It
should be noted, however, that despite
the large number of SOT recipients
enrolled (n = 1101), the majority under-
went kidney transplant (n = 670) and
were therefore at low risk for invasive
mold infection (IMI) [3]. Only 102 lung
transplant patients were included and,
not surprisingly, the colonization rate
was approximately 5-fold higher com-
pared with other SOT recipients. The
overall frequency of IMI was 2.4% and
twice as high upon lung transplant, con-
ﬁrming the high risk in this subgroup.
We performed a complementary study
in a small, yet uniform cohort of 97 pa-
tients (median age, 54 years [range, 7–
69 years]; 60% males) receiving lung
transplant between 1999 and 2012. Main
causes for transplantation were pulmo-
nary ﬁbrosis (41%), lung emphysema
(29%), and bronchiectasis (14%). Single-
lung transplant was performed in 71% of
patients, whereas the remaining underwent
bilateral transplantation. Most patients
received triple-drug immunosuppression
with a calcineurin inhibitor, prednisone,
and either azathioprine or mycopheno-
late mofetil. Colonization with Aspergillus
species was documented in 14 patients
(14%), whereas 13 (13%) were diagnosed
with proven/probable IA [4].As shown in
Table 1, the h2/h2 diplotype increased
the risk of colonization in the lungs (haz-
ard ratio [HR], 4.77; P = .01) and IA (HR,
6.69; P = .01). Of note, h2/h2 carriers also
displayed increased susceptibility to cyto-
megalovirus infection (HR, 1.80; P = .02).
These ﬁndings highlight the pivotal role
of PTX3 in binding these pathogens and
conferring protection from experimental
infection [5, 6].
Although PTX3 expression was not
evaluated, alveolar levels discriminate mi-
crobiologically conﬁrmed pneumonia in
mechanically ventilated patients [7], and
we previously established that the levels
vary individually according to host geno-
types [2]. Whether these are also geneti-
cally determined in SOT recipients in
response to infection remains to be
addressed. If conﬁrmed, we can envisage
the quantiﬁcation of PTX3 in bron-
choalveolar lavage ﬂuids as a comple-
mentary surveillance measure in addition
to the currently available diagnostic
approaches.
The integration of genetic markers into
clinically valid processes to stratify the
risk and progression of fungal infection,
and the efﬁcacy of antifungal prophylaxis
and therapy, holds the promise of a
groundbreaking innovation for patients
at risk [8]. Although the overall weight
of the antifungal immune response clear-
ly results from adding effects of single
genetic factors and their complex interac-
tions with clinical immune dysfunctions,
PTX3 represents the most robust genetic
marker identiﬁed to date. These consis-
tent ﬁndings are expected to lay the foun-
dations for well-designed prospective
trials ultimately endorsing PTX3-based
genetic testing in risk stratiﬁcation ap-
proaches for aspergillosis.
Table 1. Multivariate Analysis of Predictors of Colonization With Aspergillus Species and
Invasive Aspergillosis in Lung Transplant Recipients
Variable
Aspergillus Colonization
(n = 14) IA (n = 13)
HR (95% CI)a P Valueb HR (95% CI) P Value
PTX3 h2/h2 diplotypec 4.77 (1.43–15.9) .01 6.69 (1.57–28.5) .01
Acute/chronic rejection 4.97 (.99–25.1) .05 . . .
Recipient age (per year) . . . 1.10 (1.03–1.18) .007
Bilateral lung transplant . . . 7.56 (1.64–34.8) .009
Genetic variants in the long pentraxin 3 (PTX3) gene were independently associated with both outcomes.
Abbreviations: CI, confidence interval; HR, hazard ratio; IA, invasive aspergillosis.
a Multivariate analyses were performed by stepwise regression (P = .1). The variables included in the initial
model were recipient age and sex, cytomegalovirus infection, use of mycophenolate mofetil, calcineurin
inhibitors or corticosteroids, acute/chronic rejection, type of transplant (single-lung or bilateral), and the
PTX3 h2/h2 diplotype.
b P values and hazard ratios were assessed in the recessive genetic model (h2/h2 vs h1/h1 or h1/h2).
c The h2/h2 diplotype refers to the G-A/G-A homozygous haplotype of +281G (rs2305619) and +734A
(rs3816527).
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